Genovis AB (publ.)

kr 21.10As of Sun 8 Nov 2026, 12:00 UTC
STO:GENOHealthcare
Country Sweden
PE (Fwd) •••
TSR 10Y CAGR 22.33%
Div yield —
ROE 7.50%
Biotechnology
Beta (5Y) 1.71
PE TTM 68.15
TSR TTM (8.46%)
Mkt cap kr 1.423B
ROIC 10.15%
SE Grade™
Value
Quality
Moat
Consensus
Reference
kr 22
6.60%
17.24%
Hold 1|10|1|8|9
4Q25
1Q26
2Q26
3Q26
Earnings per sharekr
0.44
0.42
0.47
0.52
(5.94%)
(12.93%)
0.65%
13.75%
Revenuekr M
102.0
107.5
113.4
111.2
4.49%
8.70%
13.16%
7.65%
Peers (US$143.9M)
Cap (US$)
PE
156.3M
8.576x
112.2M
—
Capital
TTM
5Y
10Y
Leveragex
0.059
0.461
0.378
EBIT/Intx
3.931
0.351
0.283
Own earn%
(441.03)
(148.17)
(69.87)
Sh yield%
39.98
40.81
40.44
Owners
Insiders/Inst%
5.16
38.87
Short interest%
5.54
SBC / revenue%
0.78
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
29–32
$1 testx
—
Incr. ROIC%
12